查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1169046

注意力缺陷多動障礙治療市場：按藥物類型（興奮劑、非興奮劑）、年齡組、分銷渠道、地區 - 規模、份額、前景、機會分析，2022-2030 年

Attention Deficit Hyperactivity Disorder Treatment Market, by Drug Type (Stimulants, Non-stimulants ), by Age Group, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 181 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球注意力缺陷多動障礙 (ADHD) 治療市場包括用於治療注意力缺陷多動障礙的治療劑。 治療包括多種興奮劑，如苯丙胺、□醋甲酯、右旋苯丙胺、右旋□醋甲酯和二甲磺酸利右苯丙胺，以及非興奮劑，如托莫西汀、安非他酮、胍法辛和可樂定。 注意力缺陷多動障礙 (ADHD) 分為三種類型：注意力不集中為主、多動衝動為主和兩者兼有。 注意缺陷多動障礙 (ADHD) 的病因很多，包括腦損傷、懷孕期間飲酒和吸煙、早產和低出生體重。 注意力缺陷多動障礙是一種影響數百萬兒童的慢性疾病，並且經常持續到成年期。 患有註意力缺陷多動障礙的兒童經常在學校表現不佳和自尊心低下。 注意力缺陷多動障礙無法治愈，但可以控制症狀。 注意缺陷多動障礙的治療包括行為乾預和藥物治療。 多動症主要有註意力不集中的症狀。 ADHD 可能會增加患 ADHD 的風險，這可能是遺傳等多種因素共同作用的結果，研究人員正在研究腦部疾病、營養和社會環境如何在 ADHD 中發揮作用。我正在尋找可能的環境因素。

市場動態

主要參與者正專注於技術進步，以鞏固其在全球注意力缺陷多動障礙 (ADHD) 治療市場的地位。 例如，2020 年 6 月，數字藥物處方公司 Akili Interactive Labs 的 EndeavorRx□ (AKL-T01) 獲得了美國食品和藥物管理局的批准，這是一種治療注意力缺陷多動障礙 (ADHD) 兒童的處方藥。我得到了 EndeavorRxTM 用於治療和改善多動症兒童的注意力。

這項研究的主要特點

  • 本報告對全球注意力缺陷多動障礙治療市場進行了深入分析，包括以 2021 年為基準年的預測期 (2022-2030) 的市場規模和復合年增長率 (CAGR%)。 .
  • 它揭示了不同細分市場的潛在收入機會，並為該市場概述了一個有吸引力的投資建議矩陣。
  • 它還提供了有關市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景、主要參與者採用的競爭戰略等方面的重要見解。
  • 根據公司亮點、產品組合、主要亮點、財務業績和戰略等參數介紹全球注意力缺陷多動障礙治療市場主要參與者的概況。
  • 本研究涵蓋的主要公司包括 Amnel Pharmaceuticals LLC.、Eli Lilly And Company、Johnson & Johnson Services, Inc.、Noven Pharmaceuticals, Inc.、RespireRx Pharmaceuticals Inc、Otsuka Pharmaceutical Co., Ltd.、Neos Therapeutics , Inc.、American Brivision (Holding) Corporation、Novartis AG、Takeda Pharmaceutical Company Limited、GSK plc、Purdue Pharma L.P.、Cingulate、Adlon Therapeutics L.P.、Tris Pharma, Inc.、Neuraxpharm、Supernus Pharmaceuticals, Inc. 和 Aytu Biopharma，公司
  • 這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。我猜。
  • 全球注意力缺陷多動障礙治療市場報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
  • 利益相關者可以通過用於分析全球注意力缺陷多動障礙治療市場的各種戰略矩陣來促進他們的決策。

內容

第 1 章目的和先決條件

  • 調查目的
  • 先決條件
  • 縮寫說明

第2章市場展望

  • 報告內容
    • 市場定義和範圍
  • 執行摘要
    • 市場概況：按藥物類型
    • 市場概況：按年齡組
    • 市場概況：按分銷渠道
    • 市場概況：按地區
  • 連貫機會圖 (COM)

第3章市場動態、規律及趨勢分析

  • 市場動態
    • 司機
    • 約束因素
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 近期趨勢
  • 收購和合作場景
  • 監管情景
  • 定價分析
  • 品牌映射
  • 管道分析
  • 害蟲分析

第 4 章註意力缺陷多動障礙治療的全球市場：冠狀病毒 (COVID-19) 大流行的影響

  • 總體影響
  • 對供需的影響
  • COVID-19 對市場的影響

第 5 章註意力缺陷多動障礙治療的全球市場：按藥物類型分列，2017-2030

  • 興奮劑
  • 苯丙胺
  • □醋甲酯
  • 右旋苯丙胺
  • □醋甲酯
  • Lizdexamfetamine 二甲磺酸鹽
  • 無刺激性
  • 托莫西汀
  • 安非他酮
  • 光華申
  • 可樂定

第 6 章註意力缺陷多動障礙治療的全球市場：按年齡組劃分，2017-2030

  • 童年和青春期
  • 成人

第 7 章。全球注意力缺陷多動障礙治療市場：按分銷渠道，2017-2030

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第 8 章註意力缺陷多動障礙治療的全球市場：按地區劃分，2017-2030

  • 北美
  • 美國
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲地區
  • 歐洲
  • 英國
  • 德國
  • 意大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 東盟
  • 澳大利亞
  • 韓國
  • 其他亞太地區
  • 中東
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中非
  • 南非

第9章競爭格局

  • Amnel Pharmaceuticals LLC.
  • Eli Lilly And Company
  • Johnson & Johnson Services, Inc.
  • Noven Pharmaceuticals, Inc.
  • RespireRx Pharmaceuticals Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Neos Therapeutics, Inc.
  • American Brivision（Holding）Corporation
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • GSK plc
  • Purdue Pharma L.P.
  • Cingulate
  • Adlon Therapeutics L.P.
  • Tris Pharma, Inc.
  • Neuraxpharm
  • Supernus Pharmaceuticals, Inc.
  • Aytu Biopharma, Inc.

第10章 章節

  • 調查手法
  • 關於出版社
簡介目錄
Product Code: CMI830

The global attention deficit hyperactivity disorder (ADHD) treatment market comprises therapeutics used for the treatment of attention deficit hyperactivity disorder. There are various therapeutics such as stimulants, which include stimulant drugs such as Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate and non-stimulant drugs such as Atomoxetine, Bupropion, Guanfacine, and Clonidine. There are three types of attention deficit hyperactivity disorder (ADHD) such as predominantly inattentive presentation, predominantly hyperactive-impulsive presentation, and combined presentation. Various causes of attention deficit hyperactivity disorder (ADHD) include brain injury, alcohol and tobacco use during pregnancy, premature delivery, and low birth weight. It is a chronic condition which affects millions of children and often continue until the adulthood. Children with attention deficit hyperactivity disorder often suffer and struggle with low self-esteem and poor performance in school. Attention deficit hyperactivity disorder are not curable but can deal with symptoms. Treatment of attention deficit hyperactivity disorder involves medications as well as behavioral intervention. ADHD mainly have symptoms of inattention. ADHD probably results from a combination of factors such as genetics, researchers are looking at possible environmental factors that might raise the risk of developing ADHD and are studying how brain injuries, nutrition, and social environments might play a role in ADHD.

Market Dynamics

Key players are focusing on technological advancements to strengthen their position in the global attention deficit hyperactivity disorder (ADHD) treatment market. For instance, in June 2020, Akili Interactive Labs, a digital medicine prescription company received the U.S. Food Drug and Administration clearance for EndeavorRxTM (AKL-T01), a prescription medicine treatment for children with attention deficit hyperactivity disorder (ADHD). EndeavorRxTM is used to treat and to improve attention in children suffering from ADHD.

Key features of the study:

  • This report provides an in-depth analysis of the global attention deficit hyperactivity disorder treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global attention deficit hyperactivity disorder treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Amnel Pharmaceuticals LLC., Eli Lilly And Company, Johnson & Johnson Services, Inc., Noven Pharmaceuticals, Inc, RespireRx Pharmaceuticals Inc, Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision (Holding) Corporation, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Purdue Pharma L.P. ,Cingulate, Adlon Therapeutics L.P., Tris Pharma, Inc.,Neuraxpharm, Supernus Pharmaceuticals,Inc., and Aytu Biopharma, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global attention deficit hyperactivity disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global attention deficit hyperactivity disorder treatment market

Detailed Segmentation:

  • Global Attention Deficit Hyperactivity Disorder Treatment Market, By Drug Type:
    • Stimulants
      • Amphetamine
      • Methylphenidate
      • Dextroamphetamine
      • Dexmethylphenidate
      • Lisdexamfetamine Dimesylate
    • Non-stimulants
      • Atomoxetine
      • Bupropion
      • Guanfacine
      • Clonidine
  • Global Attention Deficit Hyperactivity Disorder Treatment Market, By Age Group:
    • Pediatric and Adolescent
    • Adult
  • Global Attention Deficit Hyperactivity Disorder Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Attention Deficit Hyperactivity Disorder Treatment Market, By Region:
    • North America
      • By Country
    • U.S.
    • Canada
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Region/Country
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Amnel Pharmaceuticals LLC.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Eli Lilly And Company
    • Johnson & Johnson Services, Inc.
    • Noven Pharmaceuticals, Inc.
    • RespireRx Pharmaceuticals Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • Neos Therapeutics, Inc.
    • American Brivision (Holding) Corporation
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
    • GSK plc
    • Purdue Pharma L.P.
    • Cingulate
    • Adlon Therapeutics L.P.
    • Tris Pharma, Inc.
    • Neuraxpharm
    • Supernus Pharmaceuticals, Inc.
    • Aytu Biopharma, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Type
    • Market Snapshot, By Age Group
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Recent Developments
  • Acquisitions and Partnerships Scenario
  • Regulatory Scenario
  • Pricing Analysis
  • Brand Mapping
  • Pipeline Analysis
  • PEST Analysis

4. Global Attention Deficit Hyperactivity Disorder Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

  • Overall Impact
  • Impact on Supply and Demand
  • COVID-19 Impact on the market

5. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Drug Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Stimulants
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Amphetamine
  • Methylphenidate
  • Dextroamphetamine
  • Dexmethylphenidate
  • Lisdexamfetamine Dimesylate
  • Non-Stimulants
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Atomoxetine
  • Bupropion
  • Guanfacine
  • Clonidine

6. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Age Group, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Pediatric and Adolescent
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Adult
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Attention Deficit Hyperactivity Disorder Treatment Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
    • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Amnel Pharmaceuticals LLC.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eli Lilly And Company
  • Johnson & Johnson Services, Inc.
  • Noven Pharmaceuticals, Inc.
  • RespireRx Pharmaceuticals Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Neos Therapeutics, Inc.
  • American Brivision (Holding) Corporation
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • GSK plc
  • Purdue Pharma L.P.
  • Cingulate
  • Adlon Therapeutics L.P.
  • Tris Pharma, Inc.
  • Neuraxpharm
  • Supernus Pharmaceuticals, Inc.
  • Aytu Biopharma, Inc.

10. Section

  • Research Methodology
  • About Us